ch505tf gp120
Vaccineexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 23, 2019 (NCT03856996)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05182125 | Phase 1 | Nov 25, 2021 | Department of Health and Human Services, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT04607408 | Phase 1 | Nov 10, 2020 | Duke University, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of the Witwatersrand |
| NCT03856996 | Phase 1 | May 23, 2019 | Emory University, National Institute of Allergy and Infectious Diseases (NIAID), Vanderbilt University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 1 | 1 | 2019 |
| HIV Vaccine Trials Network | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Department of Health and Human Services | Government | 1 | 0 | 1 | 2021 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2021 |
| University of the Witwatersrand | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2019 |
8 organizations
Page 1 / 1